Mediastinal Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mediastinal Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma [Phase 3]
Phase 3 trial evaluating nivolumab in combination with chemo-immunotherapy for newly diagnosed primary mediastinal large B-cell lymphoma is …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of epcoritamab, rituximab, gemcitabine, and oxaliplatin (R-GemOx) as salvage therapy befor…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma;…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma [Phase 1]
This ClinicalTrials.gov update describes an ongoing Phase 1 study of 19(T2)28z1xx TRAC-CAR T cells in patients with B-cell lymphomas, includ…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial evaluating CAR-T cell therapy for HIV-infected individuals with AIDS-related and other B-cell non-Hodgkin lymphomas; …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma [Phase 3]
This clinical trial update describes a Phase 3 study of nivolumab in combination with chemo-immunotherapy for newly diagnosed primary medias…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
This document provides a long-term follow-up update on allogeneic gamma delta CAR T cell therapy. The trial covers several B-cell lymphoma i…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma [Phase 1, Phase 2]
Genmab-sponsored first-in-human trial in relapsed/refractory B-cell lymphomas spans Phase 1/2 and is currently active/not recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) [Phase 1, Phase 2]
Clinical trial update announcing a Phase 1/2 study of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
A Phase 1 study of CLIC-2201 for relapsed/refractory B-cell malignancies is currently recruiting. The conditions covered include various B-c…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of NKTR-255 in combination with CAR-T cell therapy for relapsed or refractory large B-c…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]
Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CD79b-19 CAR T cells for relapsed or refractory non-Hodgkin lymphoma, including several subtypes, is cur…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of TC011 for relapsed/refractory large B-cell non-Hodgkin lymphoma, assessing safety …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T [Phase 2]
Phase 2 clinical trial evaluating Odronextamab for relapsed or refractory large B-cell lymphomas before CAR-T therapy; the study is currentl…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
This clinical trial update describes neurocognitive assessment in adults undergoing CD19-targeted CAR-T cell therapy for certain B-cell lymp…
-
CLINICAL_TRIALS other · 2026-03-05Clinical Trial Update: Pembro Plus CAR T-cell Therapy in R/R in PMBCL [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab in combination with CAR T-cell therapy for relapsed/refractory primary mediastinal large B-c…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma [Phase 1]
Phase 1 trial evaluating polatuzumab vedotin with chemotherapy, with or without glofitamab, for untreated aggressive large B-cell lymphoma. …
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update on WZTL-002 CAR T-cells for adults with relapsed large B-cell lymphoma, including DLBCL and related subtypes, …
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies [Phase 1]
Poseida Therapeutics is conducting a Phase 1 trial of P-CD19CD20-ALLO1, an allogeneic CAR-T cell therapy, for several B-cell malignancies an…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating anakinra to prevent severe CAR-T cell-related encephalopathy in patients with recurrent or refractory diffuse large…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial evaluating CC-99282 in combination with Rituximab given early after CAR T therapy in patients with relapsed or refractory B-ce…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports ongoing Phase 1/2 testing of the combination epcoritamab plus ibrutinib for relapsed or refractory aggres…